Drug Trial Radar · NCT05201404
Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis
Last checked: Nov 19, 2026Latest source record: Apr 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
471
Planned (sponsor's estimate)
Start
Mar 15, 2023
Primary completion
Feb 2026
Study completion Oct 2026
Sponsor
- Lead sponsor
- Can-Fite BioPharmaIndustry
- Sponsor type
- Industry
- First posted
- Jan 21, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a clinical trial in patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh Class B7 (CPB7) cirrhosis whose disease has progressed on at least 1st-line therapy. The trial will evaluate the efficacy and safety of namodenoson as compared to placebo.
Conditions
- Hepatocellular Carcinoma
- Cirrhosis
Interventions
NamodenosonDrug
Adenosine A3 Receptor (A3AR) agonist
PlaceboDrug
Control arm
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: From the time of randomization until the date of death from any cause, assessed up to 60 months
Locations
32 sites in 9 countries. Site status is shown where the registry gives one.
Site 881
Dallas, Texas · Not yet recruiting
841 University Clinical Centre of Republic of Srpska
Banja Luka, Bosnia and Herzegovina · Not yet recruiting
843 University Clinical Hospital Mostar
Mostar, Bosnia and Herzegovina · Not yet recruiting
842 University Clinical Centre Sarajevo
Sarajevo, Bosnia and Herzegovina · Not yet recruiting
831 Dept of Medical Oncology, Complex Oncology Ctr - Burgas EOOD
Burgas, Bulgaria · Not yet recruiting
835 First Department of Medical Oncology, Gastroenterology and Pulmology, Complex Oncology Center - Plovdiv EOOD, Plovdiv
Plovdiv, Bulgaria · Not yet recruiting
Medical Center Leo Clinic EOOD Plovdiv
Plovdiv, Bulgaria · Not yet recruiting
834 Medical Oncology Dept, Univ Multiprofile Hospital for Active Treatment "Sv. Ivan Rilski" EAD, Sofia
Sofia, Bulgaria · Recruiting
518 Rabin Medical Center Beilinson Hospital
Petah Tikva, Israel · Recruiting
872 IMSP Institute of Oncology
Chisinau, Moldova · Recruiting
Site 858
Koszalin, Poland · Not yet recruiting
Site 852
Krakow, Poland · Not yet recruiting
Site 857
Mysłowice, Poland · Not yet recruiting
Site 859
Przemyśl, Poland · Not yet recruiting
Site 855
Warsaw, Poland · Not yet recruiting
Site 850
Wroclaw, Poland · Not yet recruiting
802 Institutul Regional de Gastroenterologie si Hepatologie
Cluj-Napoca, Romania · Recruiting
807 IOCN, Medical Oncology
Cluj-Napoca, Romania · Not yet recruiting
809 Spitalul Clinic Judetean de Urgenta Constanta Oncology Dept
Constanța, Romania · Not yet recruiting
801 Oncology Center "Sf. Nectarie" Medical Oncology
Craiova, Romania · Recruiting
803 Oncolab SRL
Craiova, Romania · Recruiting
805 Euroclinic lasi
Iași, Romania · Recruiting
810 IRO Iasi-Clinica Oncologie Medicala
Iași, Romania · Recruiting
808 Spitalul Clinic Pelican Oradea Oncology Department
Oradea, Romania · Recruiting
804 Oncomed - Medical Oncology
Timișoara, Romania · Recruiting
806 Oncocenter Oncologie Clinica SRL
Timișoara, Romania · Recruiting
821 Clinic for Gastroenterology and Hepatology, Military Medical Academy
Belgrade, Serbia · Not yet recruiting
822 Oncology Institute of Vojvodina
Kamenitz, Serbia · Not yet recruiting
823 Oncology Department, Health Center Kladovo
Kladovo, Serbia · Not yet recruiting
824 Univ Clin Centre Kragujevac, Dept of Oncology
Kragujevac, Serbia · Not yet recruiting
Site 867
Banská Bystrica, Slovakia · Not yet recruiting
Site 865
Košice, Slovakia · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.